key: cord-0868302-wkn4xomv
authors: Kulasekararaj, Austin G; Lazana, Ioanna; Large, Joanna; Posadas, Kristina; Eagleton, Helen; Villajin, John Lord; Zuckerman, Mark; Gandhi, Shreyans; Marsh, Judith CW
title: Terminal complement inhibition dampens the inflammation during COVID‐19
date: 2020-06-04
journal: Br J Haematol
DOI: 10.1111/bjh.16916
sha: ccb0efce2af73960765a2fd8e0afdf4eac7d6d1b
doc_id: 868302
cord_uid: wkn4xomv

Emerging evidence suggests that activation of the complement system is critical in the pathogenesis of the novel coronavirus, SARS‐CoV‐2, the causative agent of COVID‐19 related lung injury. Inhibition of the terminal complement pathway by targeting complement protein 5 (C5) may be an effective therapeutic intervention in CoV‐mediated disease.(1) Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, acquired hematopoietic stem cell (HSC) disease characterized by intravascular haemolysis, increased thromboembolic risk and bone marrow failure.(2)

Emerging evidence suggests that activation of the complement system is critical in the pathogenesis of the novel coronavirus, SARS-CoV-2, the causative agent of COVID-19 related lung injury. Inhibition of the terminal complement pathway by targeting complement protein 5 (C5) may be an effective therapeutic intervention in CoV-mediated disease. 1 Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, acquired hematopoietic stem cell (HSC) disease characterized by intravascular haemolysis, increased thromboembolic risk and bone marrow failure. 2 The lack of GPI-linked complement regulators, especially CD55 and CD59, makes PNH erythrocytes exquisitely sensitive to complement activation, which can occur continuously, spontaneously and acutely and lead to devastating complications as a result of uncontrolled intravascular haemolysis. Precipitation of haemolysis, both in untreated patients and on those on anti-complement therapy 3 , can be induced by any complement activating events such as infection, trauma, surgery and pregnancy. Although, viral infections have been shown to induce haemolysis by activating complement, there has been no published report of COVID-19 in the context of PNH during the ongoing pandemic, neither has the added benefit of therapeutic complement inhibition, especially with monoclonal antibodies targeting C5 including eculizumab and ravulizumab been examined.

Here we report the clinical course, degree of intravascular haemolysis and outcomes of COVID-19 in 4 patients with PNH, 2 well-established on terminal complement inhibitor and 2 treatmentnaïve PNH patients.

This article is protected by copyright. All rights reserved Our index patient (patient 1, table 1) presented in mid-March 2020 with symptoms of fever (39.1 0 C), myalgia, dry cough and anosmia. She had a long-standing history of PNH and her disease activity, symptoms and haemolysis were well controlled on a long acting C5 inhibitor, ravulizumab 4 and prior to this with a first generation monoclonal antibody, eculizumab. 3 She was not hypoxic. SARS-CoV2 infection was confirmed by reverse-transcriptase-polymerase-chainreaction (RT-PCR) assay. She did not have elevated inflammatory markers and her chest radiology was normal. Interestingly, her haemolytic markers were not significantly elevated, and terminal complement was adequately inhibited, as measured by an undetectable CH50/AH50. Subsequently, we identified 3 additional PNH patients with concurrent presentation with clinical symptoms of COVID-19 and RT-PCR confirmed COVID-19 (table 1) . Two patients naïve to complement inhibitor treatment (patient 3 and 4), both with moderate/large PNH clones accompanied by a degree of haemolysis, required hospitalisation for COVID-19 pneumonia and also showed active signs of inflammation (high CRP) and worsening haemolysis (high LDH compared to baseline), due to uncontrolled complement activation. The clinical course of these two individuals, not on anti-complement therapy but on primary prophylaxis with warfarin, was protracted and needed prolonged hospitalisation, readmission and supplemental oxygen therapy. Patient 2, on high dose of eculizumab, had a similar presentation to the index patient and was found to be anaemic requiring blood transfusion, but with a clear chest radiograph, normal CRP and normal LDH.

It is clear that complement plays a key role and is an integral component of the innate immune response to pathogens and its dysregulation or activation, either due to acquired deficiency of complement regulatory proteins (i.e. PNH) or due to viral infection (i.e. SARS-CoV-2),and can lead to significant tissue damage and importantly thrombosis due to endothelial damage. 5 Our patients illustrate the presence of both conditions (PNH and COVID-19) concurrently and the differential response seen in patients already on effective complement inhibition compared to patients not on C5 inhibition. The beneficial effect of complement inhibition in not only controlling the intravascular haemolysis due to PNH, but also dampening the hyper inflammatory lung damage during COVID-19 has been illustrated with our small series. The adverse effect in patients not on C5 inhibitors may be circumstantial, as other known COVID-19

This article is protected by copyright. All rights reserved risk factors of mortality and morbidity 6 , like older age, comorbidity, high BMI and male gender could have contributed to the worse outcome.

syncytial virus), is likely to induce massive complement activation in this 'vulnerable' group and can lead to severe life-threatening complications and hospitalisation. Emerging evidence suggests that the activation of the complement system, even in the absence of PNH, is key in the pathogenesis of COVID-19-related lung injury 8 and therefore C5 inhibition may be an effective therapeutic strategy in CoV-mediated disease. Trials (SOLID-C19, CORIMUNO19-ECU and ALXN1210-COV-305), are ongoing to test the efficacy of terminal complement inhibition in dampening the progression of complications and improve outcomes in patients with COVID-19. 9

This article is protected by copyright. All rights reserved 

Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis

Natural history of paroxysmal nocturnal hemoglobinuria

Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria

Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

A Novel Coronavirus from Patients with Pneumonia in China

Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV

Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience